OTC Markets OTCQB - Delayed Quote USD

BetterLife Pharma Inc. (BETRF)

0.0800

0.0000

(0.00%)

At close: January 10 at 3:00:00 PM EST

BetterLife Announces Favorable Outcome in New York Legal Claims

VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced that the legal claims against BetterLife and its subsidiary, MedMelior Inc. (“MedMelior”) (collectively, the “Company”) have concluded in the Company’s favor such that the Company does not have any obligations

GlobeNewswire last month

BETRF
0.00%
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001

VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether-a-go-go-related gene (hE

GlobeNewswire last month

BETRF
0.00%
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001

VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxici

GlobeNewswire 2 months ago

BETRF
0.00%
BetterLife Announces Fully Subscribed Private Placement Financing

VANCOUVER, British Columbia, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, announces that it intends to complete a fully subscribed non-brokered private placement offering (the “Private Placement”) of $1,100,000. The Private Placement will comprise of units issued at a pri

GlobeNewswire 4 months ago

BETRF
0.00%
BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent

VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of 2-bromo-LSD (BETR-001), a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), today announced the publication of its patent entitled “Methods of treating mental or mood disorders using 2-bromo-LSD” (Publication No. US-2024-0058326-A1) by the United States Patent and

GlobeNewswire 4 months ago

BETRF
0.00%
Amendment of Disclosures in Past Management Information Circulars

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to

GlobeNewswire 5 months ago

BETRF
0.00%
BetterLife Announces Closing of a Private Placement

VANCOUVER, British Columbia, July 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that it has closed a non-brokered private placement, previously announced on June 13, 2024, pursuant to which the Company issued 1,750,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross pr

GlobeNewswire 6 months ago

BETRF
0.00%
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria

VANCOUVER, British Columbia, June 26, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience (Ottawa, Canada), will present data from a study investigating the mec

GlobeNewswire 6 months ago

BETRF
0.00%
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials di

GlobeNewswire 7 months ago

BETRF
0.00%
BetterLife Announces Intent to Complete Private Placement of Units

VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000. The Company intends to use the proceeds for the advancement

GlobeNewswire 8 months ago

BETRF
0.00%
BetterLife Advances BETR-001 IND-enabling Studies

VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, announces that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies

GlobeNewswire 8 months ago

BETRF
0.00%
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre. Dates:Tuesday April 16, 2024-Wednesday April 17, 2024Time:8:30 AM-5:00 PM ETLocation: Metro

Newsfile 8 months ago

BETRF
0.00%
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer, will present at the upcoming Bloom Burton Healthcare Investor Conference on Tuesda

GlobeNewswire 8 months ago

BETRF
0.00%
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

VANCOUVER, British Columbia, April 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the closing of $1.168 million of convertible debentures to further advance the development of its lead compound, BETR-001. BETR-001 is BetterLife’s proprietary 2-bromo-LSD, a non-hallucinogeni

GlobeNewswire 9 months ago

BETRF
0.00%
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University

VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its development of 2-bromo-LSD was highlighted in Carleton University’s articled titled “Beyond the Magic of Mushrooms: Using Psychedelic Derivatives to Treat Depression”. The article discusses

GlobeNewswire 10 months ago

BETRF
0.00%

Performance Overview

Return	BETRF	S&P/TSX Composite index
YTD	+6.67%	+0.60%
1-Year	+31.15%	+18.10%
3-Year	-56.28%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BetterLife Pharma Inc. (BETRF)

BetterLife Announces Favorable Outcome in New York Legal Claims

BetterLife Obtains Favourable Cardiac Safety Data for BETR-001

BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001

BetterLife Announces Fully Subscribed Private Placement Financing

BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent

Amendment of Disclosures in Past Management Information Circulars

BetterLife Announces Closing of a Private Placement

BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria

BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001

BetterLife Announces Intent to Complete Private Placement of Units

BetterLife Advances BETR-001 IND-enabling Studies

BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University

Performance Overview